Skip to main content
. 2010 Dec 20;96(4):567–573. doi: 10.3324/haematol.2010.037390

Figure 2.

Figure 2.

Circulating B-cell levels for patients having non-elevated levels at study entry. All patients received SC veltuzumab once every two weeks for a total of 4 administrations. Blood samples for B-cell levels were obtained at time of each injection and then 4, 8, 12, 24, 36, and 48 weeks after the 4th administration. Panels show results for cohorts receiving veltuzumab at 320 mg, 160 mg, or 80 mg (note change of scale for the 80 mg dose group).